ZRB2821

Anti-ACE Antibody, clone 1E15 ZooMAb^® Rabbit Monoclonal

recombinant, expressed in HEK 293 cells

• 别名: Angiotensin-converting enzyme, soluble form, Dipeptidyl carboxypeptidase I, Kininase II
• 分類程式碼代碼: 12352203

属性

• 生物源: rabbit
• 品質等級: 200
• 重組細胞: expressed in HEK 293 cells
• 共軛: unconjugated
• 抗體表格: purified antibody
• 抗體產品種類: primary antibodies
• 無性繁殖: 1E15, recombinant monoclonal
• 描述: recombinant, expressed in HEK 293 cells
• 產品線: ZooMAb^® learn more
• 形狀: lyophilized
• 分子量: calculated mol wt 149.72 kDa; observed mol wt ~200 kDa
• 純化經由: using Protein A
• 物種活性: human, rat
• 物種活性（以同源性預測）: monkey
• 包裝: antibody small pack of 25
• 環保替代產品特色: Waste Prevention; Designing Safer Chemicals; Design for Energy Efficiency; Learn more about the Principles of Green Chemistry.
• 加強驗證: recombinant expression; Learn more about Antibody Enhanced Validation
• sustainability: Greener Alternative Product
• 技術: affinity binding assay: suitable; immunofluorescence: suitable; immunohistochemistry: suitable; western blot: suitable
• 同型: IgGκ
• 表位序列: C-terminal extracellular domain
• Protein ID登錄號: NP_000780
• UniProt登錄號: P12821
• 環保替代類別: Aligned
• 運輸包裝: ambient
• 儲存溫度: 2-8°C
• 基因資訊: human ... ACE(1636)

说明

一般說明

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

特異性

Clone 1E15 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects ACE. It targets an epitope within 25 amino acids from the C-terminal extracellular domain of the protein.

免疫原

KLH-conjugated linear peptide corresponding to 25 amino acids from the C-terminal, extracellular domain of human ACE.

應用

Quality Control Testing

Evaluated by Western Blotting in human kidney tissue lysate.

Western Blotting Analysis (WB): A 1:10,000 dilution of this antibody detected ACE in human kidney tissue lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected ACE in lysates from human lung tissue and rat lung tissue.

Affinity Binding Assay: A representative lot of this antibody bound ACE peptide with at least one hundred thousand-fold (100,000X) higher than with non-specific control peptide.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected ACE in human kidney tissue sections.

Immunofluorescence Analysis: A 1:1,000 dilution from a representative lot detected ACE in human kidney tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

標靶描述

Angiotensin-converting enzyme (UniProt: P12821, EC:3.4.15.1; also known as Dipeptidyl carboxypeptidase I, Kininase II, CD143) is encoded by the ACE (also known as DCP, DCP1) gene (Gene ID: 1636) in human. Angiotensin-converting enzyme (ACE) is a single-pass type I membrane protein, a zinc metalloproteinase critical for regulating blood pressure and fluid-electrolyte balance. The enzyme exists in two main forms: ACE1 and ACE2. ACE1, the classical form, consists of two homologous domains, each containing a zinc-binding metalloprotease active site. The structure of ACE1 is characterized by a chloride-binding site that influences its catalytic activity. ACE2, while sharing similarity with ACE1 in the metalloprotease domain, lacks the second active site and functions differently in physiological processes. ACE primarily functions to convert the inactive decapeptide angiotensin I to the potent vasoconstrictor octapeptide angiotensin II, thereby regulating blood pressure. Angiotensin II also stimulates the release of aldosterone from the adrenal cortex, promoting sodium retention and further elevating blood pressure. Moreover, ACE degrades bradykinin, a vasodilator, which modulates the renin-angiotensin system′s effect on blood pressure. ACE2, conversely, counterbalances ACE1 activity by degrading angiotensin II to angiotensin 1-7, which has vasodilatory and anti-proliferative effects. ACE is widely expressed in the endothelial cells of the lungs and kidneys, vascular endothelium, epithelial cells, and other tissues. ACE2 is also expressed in the heart, kidneys, and intestines, with particularly high expression in the epithelial cells of the lungs and small intestine. The expression of ACE enzymes is regulated by physiological demand, and alterations can be indicative of or result in pathological states. ACE is predominantly a membrane-bound enzyme but also exists in a soluble form. It is primarily localized on the plasma membrane of endothelial and epithelial cells. ACE2 also shares this localization, though it is found extensively in the intestines and renal tubular cells. Dysregulation of ACE activity are implicated in several cardiovascular diseases, such as hypertension, congestive heart failure, and myocardial infarction. ACE inhibitors are commonly used in treating these conditions. Moreover, ACE2 has gained significant attention due to its role as the entry receptor for the SARS-CoV and SARS-CoV-2 coronaviruses, linking it to conditions such as COVID-19. Dysregulation of ACE2 expression is also associated with heart and kidney diseases.

外觀

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

重構

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

儲存和穩定性

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

法律資訊

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

安全信息

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 2
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable